Find research datasets worth reusing

dataset related to article: "Characteristics of Patients Returning to Work After Brain Tumor Surgery"

Dataset related to the analysis of the differences between patients returning to work and those who did not after brain tumor surgery.

dataset related to article: "Severe epilepsy in CNTNAP2 related Pitt Hopkins like syndrome successfully treated with stiripentol"

Dataset contains Sanger Sequencing Analysis: .ab1 (H1235 CNTNAP2 ex22F.ab1, H1235 CNTNAP2 ex22R.ab1) NGS analysis: .vcf (H1235)

dataset related to article: "Paroxysmal tonic upgaze in a child with SCN8A-related encephalopathy"

dataset contains Sanger Sequencing Analysis: .ab1 (S2939-SCN8A-10F.ab1, S2939-SCN8A-10R.ab1) NGS analysis: .vcf (S2939)

Dataset related to article "JNK signaling activation in the Ube3a maternal deficient mouse model"

The file contains raw data related to the article "JNK signaling activation in the Ube3a maternal deficient mouse model", available from <a href="https://www.sciencedirect.com/science/article/pii/S0969996120300875?via%3Dihu">https://www.sciencedirect.com/science/article/pii/S0969996120300875?via%3Dihub</a>.   Abstract of the manuscript Deficiency of the E3 ubiquitin ligase UBE3A leads to the neurodevelopmental disorder Angelman syndrome (AS), while higher levels are linked to autism spectrum disorder. The mechanisms underlying the downstream effects of UBE3A loss or gain of function in these disorders are still not well understood, and treatments are still lacking. Here, using the Ube3a maternal loss (Ube3am-/p+) mouse model, we report an important JNK signaling activation in the hippocampus, cortex and cerebellum correlating with the onset of behavioral defects and biochemical marker alterations in the post-synaptic element, suggesting important spine pathology. JNK activation occurs at 7 and persists up till 23 weeks in Ube3am-/p+ mice in two different cellular compartments: the nucleus and the post-synaptic protein-enriched fraction. To study JNK's role in Ube3am-/p+ pathology we treated mice with the specific JNK inhibitor peptide, D-JNKI1, from 7 to 23 weeks of age. Preventing JNK action in vivo restores the post-synaptic protein-enriched fraction defects and the cognitive impairment in these mice. Our results imply a critical role of UBE3A-JNK signaling in the pathogenesis of UBE3A-related disorders. In particular, it was clear that JNK is a key player in regulating AS synaptic alterations and the correlated cognitive impairments, in fact, its specific inhibition tackles Ube3am-/p+ pathology. This study sheds new light on the neuronal functions of UBE3A and offers new prospects for understanding the pathogenesis of UBE3A-related disorders.

Dataset related to article "WITHDRAWAL FAILURE IN PATIENTS WITH CHRONIC MIGRAINE AND MEDICATION OVERUSE HEADACHE"

The file contains baseline and follow-up data (SPSS FILES .sav) referred to the MOH-COST study, used for a secondary analysis

dataset related to article "ACCEPTANCE AND COMMITMENT THERAPY FOR HIGH FREQUENCY EPISODIC MIGRAINE WITHOUT AURA FINDINGS FROM A RANDOMIZED PILOT INVESTIGATION"

Dataset including data (SSPS files .sav) referred to the Italian subsample of the “ACT for Migraine” multicenter study

dataset related to article: "Spastic paraplegia type 46: novel and recurrent GBA2 gene variants in a compound heterozygous Italian patient with spastic ataxia phenotype"

Dataset contains Genetic data in VCF format of an Italian patient with spastic ataxia phenotype

dataset related to article: "ATTRV COLLABORATORS. PSYCHOSOCIAL BURDEN AND PROFESSIONAL AND SOCIAL SUPPORT IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (ATTRV) AND THEIR RELATIVES IN ITALY"

dataset contains information on psychosocial and demographic characteristics of ATTRv patients and relatives

Dataset related to article" Hypomyelinating leukodystrophies in adults: Clinical and genetic features."

Dataset contains genetic data (including NGS, Sanger and Multiplex ligation-dependent probe amplification analysis) of a cohort of patients with hypomyelinating leukodystrophies

Dataset related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study"

The file contains raw data related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study", available from <a href="https://onlinelibrary.wiley.com/doi/10.1002/pds.5159">https://onlinelibrary.wiley.com/doi/10.1002/pds.5159</a>.   Abstract of the manuscript: Purpose: We examined data collected in the Monzino 80-plus study to assess the relations between cognitive performance and ACB scores according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance. Methods: The Monzino 80-plus is an ongoing, prospective, door-to-door population-based study started in 2002 among all residents 80 years or older in eight municipalities of Varese province, Italy. To establish the relation between cognitive impairment and the anticholinergic drug burden we recorded the ACB score for each patient at baseline. The relations between ACB score and dementia or MMSE scores were also examined after exclusion of patients taking any antipsychotic. Results: A sample of 2140 elderly people was eligible for analysis. A significant dose-effect relationship was observed between total ACB score and diagnosis of dementia in univariate and multivariate models. Patients in ACB class ≥4 had about 4.5 times the risk of diagnosis of dementia. A relation was also found between higher ACB scores and lower MMSE scores; patients who scored 4 or more had a mean of 6.4 points lower than those not taking anticholinergic drugs. The dose-effect relationship between ACB score and diagnosis of dementia was not maintained after exclusion of patients using antipsychotics, while the association between higher ACB scores and lower MMSE scores was still present, with patients in ACB class ≥4 having a mean score about 4.4 lower. Conclusions: There are clear relations between anticholinergic load and reduced cognitive performance, while the association with dementia remains uncertain. For primary care and geriatric clinicians, an ACB score ≥ 4 can be considered the cut-off to identify high-risk populations who may benefit from the evaluation of anticholinergic burden with the ACB scale.

restrictedOct 2022View details →

Dataset related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"

This record contains raw data related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy" Abstract Purpose: Total marrow (and lymphoid) irradiation (TMI-TMLI) is limited by the couch travel range of modern linacs, which forces to split the treatment delivery into two plans with opposite orientations: a head-first supine upper-body plan, and a feet-first supine lower-extremities plan. A specific field junction is thus needed to obtain adequate target coverage in the overlap region of the two plans. In this study, an automatic procedure was developed for field junction creation and lower-extremities plan optimization. Methods: Ten patients treated with TMI-TMLI at our institution were selected retrospectively. The planning of the lower-extremities was performed automatically. Target volume parameters (CTV_J-V98%>98%) at the junction region and several dose statistics (D98%, Dmean, and D2%) were compared between automatic and manual plans. The Modulation Complexity Score (MCS) was used to assess plan complexity. Results: The automatic procedure required 60-90 minutes, depending on the case. All automatic plans achieved clinically acceptable dosimetric results (CTV_J-V98%>98%), with significant differences found at the junction region, where Dmean and D2% increased on average by 2.4% (p<0.03) and 3.0% (p<0.02), respectively. Similar plan complexity was observed (median MCS=0.12). Since March 2022 the automatic procedure has been introduced in our clinic, reducing the TMI-TMLI simulation-to-delivery schedule by 2 days. Conclusions: The developed procedure allowed to streamline the treatment planning of TMI-TMLI, increasing efficiency and standardization, preventing human errors, while maintaining the dosimetric plan quality and complexity of manual plans. Automated strategies can simplify the future adoption and clinical implementation of TMI-TMLI treatments in new centers.

Dataset related to article "Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma"

This record contains data related to article “Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma” Background: The different oncological outcomes of invasive intraductal papillary mucinous neoplasm (I-IPMN) and pancreatic ductal adenocarcinoma (PDAC) are debated. This study aimed to compare disease recurrence patterns and histopathological characteristics in patients with resected I-IPMN and PDAC. Methods: Consecutive patients undergoing surgical resection for stage I-III I-IPMN or PDAC between 2010 and 2016 were retrospectively analyzed. Patients treated with neoadjuvant therapy or resected for Tis neoplasia were excluded. All surgical specimens were re-staged according to AJCC-8th-edition. Results: A total of 330 patients were included, of whom 43 had I-IPMN and 287 had PDAC. Median follow-up time was 26.7 (1.3-92.3) months and estimated median disease-free survival (DFS) was 60.3 months (47.2-73.4) for I-IPMN and 23.8 (19.3-28.2) months for PDAC (p < 0.001). During follow-up, 32.6% of I-IPMN and 67.9% of PDAC patients experienced recurrence (p < 0.001). The sites of first recurrence were the lungs (38.5% vs 13.1%, p = 0.027), liver (28.6% vs 45.0%, p = 0.180) and local (15.4% vs 36.6%, p = 0.101) for I-IPMN and PDAC, respectively. At multivariate analysis, I-IPMN histology remained an independent predictive factor for longer DFS (OR 0.528, CI 95% 0.278-1.000, p = 0.050), regardless of stage or adjuvant chemotherapy. I-IPMN and PDAC differed in rates of neuroinvasion (51.2% vs 97.2%) and positive lymph node status (N+) (46.5% vs 82.7%), especially in patients with lower T status. Conclusion: I-IPMN showed a different recurrence pattern compared to PDAC, with a higher lung tropism, and longer DFS. This different biological behavior is associated with lower rates of neuroinvasion and nodal involvement, especially in early-stage disease.

Dataset related to article [18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis

[18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis

Dataset related to the article "GRN- /- IPSC-DERIVED CORTICAL NEURONS RECAPITULATE THE PATHOLOGICAL FINDINGS OF BOTH FRONTOTEMPORAL LOBAR DEGENERATION AND NEURONAL CEROIDOLIPOFUSCINOSIS"

THE DATASET CONTAINS .XLSX FILES REPORTING BIOCHEMICAL DATA (DENSITOMETRIC ANALYSIS) AND IMMUNOHISTOCHEMICAL DATA (MORPHOMETRIC ANALYSIS AND COUNTING)

Dataset related to article "Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab "

This record contains raw data related to article “Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab" Abstract Background and objective: Background: Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, has been recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, demonstrating a rapid onset of clinical effects. CRSwNP is characterized by an extended type-2 inflammatory involvement that can be assessed by extended nitric oxide analysis. Objective: In this study we investigated whether Dupilumab is associated with a rapid improvement in extended nitric oxide parameters, lung function and clinical outcomes in patients with CRSwNP. Methods: : Consecutive patients with CRSwNP and indication to be treated with Dupilumab were evaluated for extended nitric oxide analysis (exhaled, FENO; bronchial, JawNO and alveolar, CalvNO components; nasal, nNO) and lung function 15 and 30 days after treatment initiation, and for clinical outcomes (nasal polyps score, NPS; quality of life questionnaires; visual analogue scales, VAS, for main symptoms, asthma control test, ACT) after 30 days of treatment initiation. Results: 33 patients were enrolled. All extended nitric oxide and lung function parameters significantly improved after 15 days of treatment remaining stable at 30 days. NPS, VAS for main CRSwNP symptoms, quality of life questionnaires and ACT significantly improved after 30 days of treatment initiation. Conclusion: Dupilumab is associated with very rapid improvement in type 2 inflammation in all airway districts and this is associated with improved lung function and clinical parameters in patients with CRSwNP.

Dataset related to article "Tentorial Notch Meningiomas: Innovative Preoperative Management and Literature Review"

This record contains raw data related to article “Tentorial Notch Meningiomas: Innovative Preoperative Management and Literature Review" Abstract Background: Tentorial meningiomas account for only 3-6% of all intracranial meningiomas. Among them, tentorial incisura (notch) location must be considered as a subgroup with specific surgical anatomy and indications, morbidity, and mortality. In this study, we propose an update on preoperative management in order to reduce postoperative deficits. Methods: We retrospectively collected adult patients treated for incisural meningioma between January 1992 and December 2016 in two different neurosurgical departments. Demographic, clinical, and neuroradiological preoperative and postoperative data were analyzed. In the most recent subgroup of tumors, a preoperative digital simulation was performed to define a volumetric digital quantification of the tumor resection. A review of the pertinent literature has been also done. Results: We included 26 patients. The median age was 58.4 years. Onset neurological signs were cranial nerve deficit in 9 patients, hemiparesis in 7, gait disturbance in 3, and intracranial hypertension in 3 patients. Simpson grade I removal was achieved in 12 patients, II in 10, III in 3, and IV in 1 patient. An overall rate of 23% postoperative complications was observed. The average follow-up duration was 68.5 months. Residual tumor was reported in 8 patients. Five patients underwent gamma knife radiosurgery. In 34.6% of patients, the surgical approach was chosen with preoperative digital planning estimating the potential volume of postoperative residual tumor, the target for radiosurgical treatment. Conclusions: A multidisciplinary approach to plan incisural meningiomas management is important. To lower postoperative morbidity and mortality, a careful preoperative case analysis is useful. A planned residual tumor, supported by preoperative simulation imaging, could be safely treated with radiosurgery.

Dataset related to article "Left atrial appendage closure with the II generation Ultraseal device: An international registry. The LIGATE study "

This record contains raw data related to article "Left atrial appendage closure with the II generation Ultraseal device: An international registry. The LIGATE study " Abstract Objectives: To assess feasibility and safety of second-generation left atrial appendage closure (LAAC) Ultraseal device in patients with nonvalvular atrial fibrillation (NVAF). Background: LAAC with first-generation Ultraseal device (Cardia, Eagan, Minnesota) has been shown to be a feasible therapeutic option in patients with NVAF. However, there is a paucity of data regarding the novel second-generation Ultraseal device. Methods: All patients with NVAF undergoing second-generation Ultraseal device implantation between February 2018 and September 2020 were included in a multicenter international registry. Periprocedural and post-discharge events were collected through 6-month follow-up. Co-primary efficacy endpoints were device success and technical success while primary safety endpoint was in-hospital major adverse event (MAE) occurrence. Results: A total of 52 patients were included: mean age 75 ± 8, 30.8% women, mean HAS-BLED 3 ± 1. The device was successfully implanted in all patients. Technical success was achieved in 50 patients (96.1%). In-hospital MAEs occurred in three patients (5.8%). The incidence of 6-month all-cause death and major bleeding was 11.6% and 2.1%, respectively. No strokes, transient ischemic attacks, systemic embolisms, or device embolization were reported after discharge. Conclusions: Second-generation Ultraseal device implantation was associated with high success rates and a low incidence of peri-procedural complications. Larger studies with longer follow-up are warranted to further evaluate the safety and the efficacy of this device, especially at long-term follow-up.

Dataset related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients"

This record contains raw data related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients" Abstract: Background It is unknown whether contemporary drug-eluting stents have a similar safety profile in high bleeding risk patients treated with 1-month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional, prospective, multicenter, single-arm trial, powered for noninferiority with respect to an objective performance criterion to evaluate the safety of percutaneous coronary interventions with Synergy bioresorbable-polymer everolimus-eluting stent followed by 1-month dual antiplatelet therapy in patients with high bleeding risk. In case of need for an oral anticoagulant, patients received an oral anticoagulant in addition to a P2Y12 inhibitor for 1 month, followed by an oral anticoagulant only. The primary end point was the composite of cardiac death, myocardial infarction, or definite or probable stent thrombosis at 1-year follow-up. The study was prematurely interrupted because of slow recruitment. From April 2017 to October 2019, 443 patients (age, 74.8±9.2 years; women, 29.1%) at 10 Italian centers were included. The 1-year primary outcome occurred in 4.82% (95% CI, 3.17%-7.31%) of patients, meeting the noninferiority compared with the predefined objective performance criterion of 9.4% and the noninferiority margin of 3.85% (Pnoninferiority<0.001) notwithstanding the lower-than-expected sample size. The rates of cardiac death, myocardial infarction, and definite or probable stent thrombosis were 1.88% (95% CI, 0.36%-2.50%), 3.42% (95% CI, 2.08%-5.62%), and 0.94% (95% CI, 0.35%-2.49%), respectively. Conclusions Among high bleeding risk patients undergoing percutaneous coronary interventions with the Synergy bioresorbable-polymer everolimus-eluting stent, a 1-month dual antiplatelet therapy regimen is safe, with low rates of ischemic and bleeding events. Registration URL: https://www.clinicaltrials.gov; Unique identifier: <a href="http://clinicaltrials.gov/show/NCT03112707">NCT03112707</a>.

Dataset related to article "Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis"

This record contains raw data related to article “Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis" Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition substantially impacting patients’ quality of life, typically associated with type inflammation and frequent comorbidities like asthma, and/or nonsteroidal anti-inflammatory drug exacerbated respiratory disease (N-ERD). So far, there is minimal awareness and understanding of possible genetic factors associated with CRSwNP, apart from patients with a clear genetic disorder such as cystic fibrosis. The aims of this study were to assess the prevalence of familial link in a large cohort of patients affected by CRSwNP and to evaluate whether it was associated with specific phenotypes.

Dataset related to article "Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps "

This record contains raw data related to article “Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps" Abstract To date, no disease-specific tool has been available to assess the impact of chronic rhinosinusitis with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). Therefore, the purpose of this study was to develop and validate a questionnaire specifically designed to this aim: the Nasal Polyposis Quality of Life (NPQ) questionnaire. As indicated in the current guidelines, the development and validation of the NPQ occurred in two separate steps involving different groups of patients. The questionnaire was validated by assessing internal structure, consistency, and validity. Responsiveness and sensitivity to changes were also evaluated. In the development process of NPQ an initial list of 40 items was given to 60 patients with CRSwNP; the 27 most significant items were selected and converted into questions. The validation procedure involved 107 patients (mean age 52.9 ± 12.4). NPQ revealed a five-dimensional structure and high levels of internal consistency (Cronbach's alpha 0.95). Convergent validity (Spearman' coefficient r = 0.75; p < 0.01), discriminant validity (sensitivity to VAS score), and reliability in a sample of patients with a stable health status (Interclass Coefficient 0.882) were satisfactory. Responsiveness to clinical changes was accomplished. The minimal important difference was 7. NPQ is the first questionnaire for the assessment of HRQoL in CRSwNP. Our results demonstrate that the new tool is valid, reliable, and sensitive to individual changes.